These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 29668120)

  • 1. Cytomegalovirus infection in living donor liver transplant recipients significantly impacts the early post-transplant outcome: A single center experience.
    Yadav SK; Saigal S; Choudhary NS; Saha S; Sah JK; Saraf N; Kumar N; Goja S; Rastogi A; Bhangui P; Soin AS
    Transpl Infect Dis; 2018 Aug; 20(4):e12905. PubMed ID: 29668120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
    Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
    Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus infection in heart transplantation: A single center experience.
    Echenique IA; Angarone MP; Rich JD; Anderson AS; Stosor V
    Transpl Infect Dis; 2018 Aug; 20(4):e12896. PubMed ID: 29602266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
    Reusing JO; Feitosa EB; Agena F; Pierrotti LC; Azevedo LSF; Kotton CN; David-Neto E
    Transpl Infect Dis; 2018 Oct; 20(5):e12929. PubMed ID: 29809309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.
    Mengelle C; Rostaing L; Weclawiak H; Rossignol C; Kamar N; Izopet J
    J Med Virol; 2015 May; 87(5):836-44. PubMed ID: 25655981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
    Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
    Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection?
    Singh N; Wannstedt C; Keyes L; Wagener MM; Cacciarelli TV
    Liver Transpl; 2005 Jun; 11(6):700-4. PubMed ID: 15915496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: A prospective, observational, multicenter study.
    Monforte V; Sintes H; López-Gallo C; Delgado M; Santos F; Zurbano F; Solé A; Gavaldá J; Borro JM; Redel-Montero J; Cifrian JM; Pastor A; Román A; Ussetti P
    Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28294487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.
    Heldenbrand S; Li C; Cross RP; DePiero KA; Dick TB; Ferguson K; Kim M; Newkirk E; Park JM; Sudaria-Kerr J; Tichy EM; Ueda KR; Weng R; Wisniewski J; Gabardi S
    Transpl Infect Dis; 2016 Dec; 18(6):904-912. PubMed ID: 27639246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
    Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
    Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Living donor liver transplantation during the first 3 months of life.
    Kasahara M; Sakamoto S; Sasaki K; Uchida H; Kitajima T; Shigeta T; Narumoto S; Hirata Y; Fukuda A
    Liver Transpl; 2017 Aug; 23(8):1051-1057. PubMed ID: 28220684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus infection in renal transplant recipients: one center's experience.
    Bal Z; Uyar ME; Tutal E; Erdogan E; Colak T; Sezer S; Haberal M
    Transplant Proc; 2013; 45(10):3520-3. PubMed ID: 24314948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed-onset primary cytomegalovirus disease after liver transplantation.
    Arthurs SK; Eid AJ; Pedersen RA; Dierkhising RA; Kremers WK; Patel R; Razonable RR
    Liver Transpl; 2007 Dec; 13(12):1703-9. PubMed ID: 18044717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of post-prophylaxis cytomegalovirus infection in lung transplant recipients.
    Jaamei N; Koutsokera A; Pasquier J; Mombelli M; Meylan P; Pascual M; Aubert JD; Manuel O
    Transpl Infect Dis; 2018 Aug; 20(4):e12893. PubMed ID: 29603543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of donor and recipient cytomegalovirus serology on long-term survival of lung transplant recipients.
    Mabilangan C; Preiksaitis J; Cervera C;
    Transpl Infect Dis; 2018 Oct; 20(5):e12964. PubMed ID: 29981174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.
    Fleming JN; Taber DJ; Weimert NA; Nadig S; McGillicuddy JW; Bratton CF; Baliga PK; Chavin KD
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of donor-recipient cytomegalovirus serology on adult liver transplantation: a single center experience.
    Tryphonopoulos P; Weppler D; Morris MI; Russo C; Nishida S; Levi DM; Moon J; Tekin A; Selvaggi G; Island E; Arosemena L; Ruiz P; Tzakis AG
    Transplantation; 2011 Nov; 92(9):1051-7. PubMed ID: 21876474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients.
    Fayek SA; Mantipisitkul W; Rasetto F; Munivenkatappa R; Barth RN; Philosophe B
    HPB (Oxford); 2010 Dec; 12(10):657-63. PubMed ID: 21083790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparable Short- and Long-term Outcomes in Living Donor and Deceased Donor Liver Transplantations for Patients With Model for End-stage Liver Disease Scores ≥35 in a Hepatitis-B Endemic Area.
    Chok KS; Fung JY; Chan AC; Dai WC; Sharr WW; Cheung TT; Chan SC; Lo CM
    Ann Surg; 2017 Jan; 265(1):173-177. PubMed ID: 28009743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.